Table 4.
Univariate analyses for Overall Survival, Progression-Free Survival, Relapse and NRM in patients transplanted for graft failure.
| Overall survival | Progression-free survival | Relapse | Non-relapse mortality | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| N | 2 years | p value | N | 2 years | p value | 2 years | p value | 2 years | p value | |
| All | 56 | 41% (28–54%) | 50 | 34% (21–47%) | 32% (19–45%) | 34% (21–47%) | ||||
| Patient gender | ||||||||||
| Male | 24 | 41% (21–61%) | 0.771 | 22 | 31% (12–51%) | 0.925 | 28% (9–47%) | 0.538 | 41% (20–61%) | 0.489 |
| Female | 32 | 41% (24–59%) | 28 | 36% (18–53%) | 36% (18–53%) | 29% (12–45%) | ||||
| Donor type | ||||||||||
| HLAid-Sib-HLAid-Sib | 20 | 32% (11–52%) | 0.699 | 18 | 28% (7–48%) | 0.699 | 39% (16–61%) | 0.429 | 33% (12–55%) | 0.726 |
| Other | 34 | 47% (30–64%) | 31 | 35% (18–52%) | 29% (13–45%) | 35% (19–52%) | ||||
| Interval between allos | ||||||||||
| <1 year | 44 | 37% (22–51%) | 0.266 | 38 | 37% (22–52%) | 0.585 | 26% (12–40%) | 0.147 | 37% (22–52%) | 0.567 |
| ≥1 year | 12 | 58% (30–86%) | 12 | 25% (1–49%) | 50% (22–78%) | 25% (1–49%) | ||||
| Disease status | ||||||||||
| Low | 29 | 37% (19–55%) | 0.147 | 28 | 28% (11–45%) | 0.21 | 22% (6–37%) | 0.184 | 50% (31–69%) | 0.016 |
| Advanced | 19 | 61% (39–84%) | 17 | 47% (23–71%) | 41% (18–65%) | 12% (0–27%) | ||||
| Year at second allo | ||||||||||
| 1994–2008 | 28 | 33% (15–51%) | 0.341 | 23 | 39% (19–59%) | 0.458 | 22% (5–39%) | 0.191 | 39% (19–59%) | 0.65 |
| After 2008 | 28 | 49% (30–68%) | 27 | 30% (12–47%) | 41% (22–59%) | 30% (12–47%) | ||||
| Age at second allo | ||||||||||
| <50 years | 29 | 44% (26–63%) | 0.868 | 27 | 37% (19–55%) | 0.873 | 30% (12–47%) | 0.816 | 33% (16–51%) | 0.942 |
| 50–70 years | 27 | 38% (19–57%) | 23 | 30% (12–49%) | 35% (15–54%) | 35% (15–54%) | ||||
| Karnofsky score | ||||||||||
| <90 | 13 | 62% (35–88%) | 0.345 | 13 | 38% (12–65%) | 0.488 | 38% (12–65%) | 0.684 | 23% (0–46%) | 0.269 |
| 90–100 | 16 | 42% (16–67%) | 16 | 25% (4–46%) | 31% (9–54%) | 44% (19–68%) | ||||
| Stem cell source | ||||||||||
| BM | 6 | 50% (10–90%) | 0.582 | 6 | 50% (10–90%) | 0.349 | 17% (0–46%) | 0.367 | 33% (0–71%) | 0.904 |
| PB | 49 | 39% (25–53%) | 43 | 30% (16–44%) | 35% (21–50%) | 35% (21–49%) | ||||
| Conditioning intensity | ||||||||||
| Standard | 15 | 39% (14–64%) | 0.823 | 12 | 33% (7–60%) | 0.845 | 42% (14–70%) | 0.754 | 25% (1–49%) | 0.711 |
| Reduced | 33 | 46% (29–64%) | 30 | 36% (19–54%) | 34% (17–51%) | 30% (14–46%) | ||||
| MM | ||||||||||
| IgG | 25 | 44% (25–63%) | 0.834 | 22 | 40% (20–61%) | 0.629 | 28% (9–47%) | 0.637 | 32% (12–51%) | 0.879 |
| IgA | 13 | 31% (6–56%) | 12 | 25% (1–49%) | 42% (14–70%) | 33% (7–60%) | ||||
| Light chain | 18 | 46% (22–70%) | 16 | 31% (9–54%) | 31% (9–54%) | 38% (14–61%) | ||||
| EBMT risk score | ||||||||||
| <5 | 11 | 34% (5–63%) | 0.682 | 11 | 34% (5–63%) | 0.867 | 20% (0–46%) | 0.527 | 45% (16–75%) | 0.826 |
| 5 | 22 | 43% (22–64%) | 19 | 37% (15–59%) | 32% (11–52%) | 32% (11–52%) | ||||
| >5 | 15 | 52% (27–78%) | 15 | 27% (4–49%) | 40% (15–65%) | 33% (9–57%) | ||||
Bold values indicate statistical significance p < 0.05.